Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer
Received: 20 March 1997 Accepted: 16 September 1997 DOI:
Cite this article as: Sosa, J.A., Diener-West, M., Gusev, Y. et al. Annals of Surgical Oncology (1998) 5: 140. doi:10.1007/BF02303847 Abstract Background: The role of axillary lymph node dissection for stage I (T1N0) breast cancer remains controversial because patients can receive adjuvant chemotherapy regardless of their nodal status and because its therapeutic benefit is in question. The purpose of this study was to determine whether extent of axillary dissection in patients with T1N0 disease is associated with survival. Methods: Data from 464 patients with T1N0 breast cancer who underwent axillary dissection from 1973 to 1994 were examined retrospectively. Kaplan-Meier estimates of overall survival, disease-free survival, and recurrence were calculated for patients according to the number of lymph nodes removed (<10 or ⩾10; <15 or ⩾15), and survival curves compared using the Wilcoxon-Gehan statistic. Cox proportional hazards regression modelling was used to adjust for confounding prognostic variables. Results: Median follow-up time was 6.4 years. Patient groups were similar in age, menopausal status, tumor size, hormonal receptor status, type of surgery, and adjuvant therapy. There was a statistically significant improvement in disease-free survival in the ⩾10 versus <10 nodal groups ( P<.01). Five-year estimates of survival were 75.7% and 86.2% for <10 nodes and ⩾10 nodes, respectively; 10-year estimates were 66.1% and 74.3%. There also was a notable improvement in the survival comparison of patients with <15 versus ⩾15 nodes ( P⩽.05). These findings were confirmed in the multivariate analysis. Conclusions: These results may reflect a potential for misclassification of tumor stage among patients who had fewer nodes removed. The data, however, suggest that in patients with Stage I breast cancer, improved survival is associated with a more complete axillary lymph node dissection. Key Words Breast cancer Axillary dissection Survival
Presented at the 50th Annual Cancer Symposium of The Society of Surgical Oncology, Chicago, Illinois, March 20–23, 1997.
Miller BA, Feuer EJ, Hankey BF. Recent incidence trends for breast cancer in women and the relevance of early detection: an update.
CA Cancer J Clin
McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients (commentary).
J Natl Cancer Inst
Cabanes PA, Salmon RJ, Vilcoq JR, Durand JC, Fourquet A, Gautier C, Asselain B, for the Breast Carcinoma Collaborative Group of the Institut Curie. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer.
Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation.
N Engl J Med
Atkins H, Jayward JL, Klugman DJ, Wayte AB. Treatment of early breast cancer: a report after 10 years of a clinical trial.
Br Med J
Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer.
Graversen HP, Blichert-Toft M, Andersen JA, Zedler K, and the Danish Breast Cancer Cooperative Group. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla.
Eur J Surg Onc 1988;14:407–12.
Rose CM, Botnick LE, Weinstein M, Harris JR, Koufman C, Silen W, Hellman S. Axillary sampling in the definitive treatment of breast cancer by radiation therapy and lumpectomy.
Int J Radiat Oncol Biol Phys
Axelsson CK, Mouridsen HT, Zedeler K, on behalf of The Danish Breast Cancer Cooperative Group (DBCG). Axillary dissection of level I and II lymph nodes is important in breast cancer classification.
Eur J Cancer
Veronesi U, Salvadori B, Luini A, et al. Breast conservation is a safe method in patients with small cancer of the breast: long-term results of three randomised trials on 1,973 patients.
Eur J Cancer
White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HJ, Bland KI. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
J Am Coll Surg
Kay R, Schumacher M. Unbiased assessment of treatment effects on disease recurrence and survival in clinical trials.
Statistics in Medicine
Kaplan E, Meier P. Nonparametric estimation from incomplete observations.
J Amer Stat Assoc 1958;53:457–81.
Gehan E. A generalized Wilcoxon test for comparing arbitrarily singly censored samples.
Cox DR. Regression models and life tables.
J Roy Statist Soc Bull 1972;34:187–202.
Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy.
Fisher B, Slack N, Katrych D, Wolmark N. Ten-year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy.
Surg Gynecol Obstet
Sigel B, Mayzel K, Love S. Level I and II axillary dissection in the treatment of early-stage breast cancer.
Arch Surg 1990;125:11–14.
Moffat FL, Senofsky GM, Davis K, Clark KC, Robinson DS, Ketcham AS. Axillary node dissection for early breast cancer: some is good, but all is better.
J Surg Oncol
Hellman S. Natural history of small breast cancers (Karnofsky memorial lecture).
J Clin Oncol
Dewar JA, Sarrazin D, Benhamou E, et al. Management of the axilla in conservatively treated breast cancer: 592 patients treated at Institut Gustave-Roussy.
Int J Radiat Biol Phys 1987;13:475–81.
Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast.
Surg Gynecol Obstet
Wilson RE, Donegan WL, Mettlin C, Natarajan N, Smart CR, Murphy GP. The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons.
Surg Gynecol Obstet 1989;159:309–18.
Carter C, Allen C, Henson D. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.
Davies GC, Millis RR, Hayward JL. Assessment of axillary lymph node status.
Ann Surg 1990;192:148–51.
Kissin MW, Thompson EM, Price AB, Slavin G, Kark AE. The inadequacy of axillary sampling in breast cancer.
Kjaergaard J, Blichert-Toft M, Andersen JA, Rank F, Pedersen BV, and the Danish Breast Cancer Cooperative Group. Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer.
Br J Surg
Mathiesen O, Carl J, Bonderup O, Panduro J. Axillary sampling and the risk of erroneous staging of breast cancer: an analysis of 960 consecutive patients.
E-3193, Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary nodenegative receptor-positive breast cancer ⩽3 cm. Denver, CO: Eastern Cooperative Oncology Group, 1996:5.
Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.
N Engl J Med
Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy.
Ann Surg 1995;222:393–401. Copyright information
© The Society of Surgical Oncology, Inc. 1998